£500,000 award towards major international trauma research

16 Feb 2017

As part of our dedication to reducing deaths and disability from trauma, we are helping to fund a landmark international clinical trial to evaluate a new treatment in major traumatic haemorrhage.

 

Barts Charity Trauma Research

Principal Investigator Dr Ross Davenport from the Queen Mary University of London (QMUL) Centre for Trauma Sciences (C4TS) said: “Major haemorrhage is the most common preventable cause of death in the trauma population, with most deaths occurring within the first six hours after injury.  As many as four in every 10 patients affected by severe trauma die from uncontrolled bleeding."

In total, £2.4 million has been awarded to QMUL and NHS Blood & Transplant for the trial; £500,000 from Barts Charity and the remainder from the National Institute for Health Research.

The grant will be used by C4TS to run the CRYOSTAT-2 trial which will examine the use of cryoprecipitate; a concentrated source of fibrinogen which is a protein found in the blood that helps form clots and stop bleeding.

The protein is already used as a treatment for patients with major bleeding, however, transfusion typically occurs three hours or more after arrival in the Emergency Department. CRYOSTAT-2 will instead look into the effects of delivering cryoprecipitate within 90 minutes of admission.

Dr Davenport added: “Fibrinogen is a blood protein essential for forming clots and replacing it early with specific fibrinogen-rich blood transfusions may save lives. This will be the first national transfusion study in the UK since trauma networks were established in England and Wales. Improved transfusion practices have the potential to save millions of lives globally.”

More news